Drug designer: New tool reveals mutations that cause HIV-drug resistance
Protease inhibitor drugs are one of the major weapons in the fight against HIV, the virus that causes AIDS, but their effectiveness is limited as the virus mutates and develops resistance to the drugs over time. Now a new tool has been developed to help predict the location of the mutations that lead to drug resistance.
First discovered in 1995, protease inhibitor drugs have dramatically reduced the number of AIDS deaths. Taken in combination with two other anti-HIV drugs, protease inhibitors work by halting the action of the protease enzyme, a protein produced by HIV that is necessary for replication of the virus. However, almost half of HIV patients who initially respond to treatment with protease inhibitors develop drug-resistance strains and stop responding to treatment within eight to 10 months.
Currently there are nine FDA approved protease inhibitors, and 21 most common drug-resistant mutations.
The main reason for the short-term effectiveness of the drug has to do with the evolution of the drug within the body, said the study's author, Yi Mao, a postdoctoral fellow at the National Institute for Mathematical and Biological Synthesis.
In the new study, published today in the journal BMC Structural Biology, Mao used a mathematical modeling technique called elastic network modeling to examine the physical properties and interactions of the proteins. The model reveals where mutations are occurring during the evolution of the HIV-virus proteins and how these mutations help the virus survive.
"With this kind of knowledge, better strategies for designing anti-HIV drugs could be developed," Mao said.
HIV kills the body's immune system cells, called CD4 cells. Once the number of CD4 cells dips below 200, an HIV patient enters the last stage of his or her disease: Acquired Immune Deficiency Syndrome, or AIDS. The first cases of AIDS were reported thirty years ago. Since then, more than 60 million people have been infected with HIV, and more than 30 million people have died from AIDS. Today an estimated 34 million people worldwide are living with HIV 1.2 million in the U.S.
More information: Mao Y. 2011. Dynamical Basis for Drug Resistance of HIV-1 Protease. BMC Structural Biology. Published online 8 July 2011. 11:31. doi:10.1186/1472-6807-11-31
Provided by National Institute for Mathematical and Biological Synthesis
-
Researchers find drug-resistant HIV patients with unimpaired immune cells
Nov 30, 2010 |
not rated yet |
0
-
HIV isolate from Kenya provides clues for vaccine design
Jan 02, 2008 |
not rated yet |
0
-
Researchers trace HIV mutations that lead to drug resistance
Jan 11, 2010 |
not rated yet |
0
-
Rutgers researchers discover how HIV resists AZT
Sep 19, 2010 |
not rated yet |
0
-
Sensitive testing reveals drug-resistant HIV with possible consequences for treatment
Jul 29, 2008 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011
- More from Physics Forums - Independent Research
More news stories
After a decade, global AIDS program looks ahead
(AP)—The decade-old law that transformed the battle against HIV and AIDS in developing countries is at a crossroads. The dream of future generations freed from the epidemic is running up against an era ...
HIV & AIDS
5 hours ago |
not rated yet |
0
'Gap' for HIV vaccine efforts after latest setback
The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.
HIV & AIDS
May 19, 2013 |
5 / 5 (1) |
0
AIDS science at 30: 'Cure' now part of lexicon
Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.
HIV & AIDS
May 18, 2013 |
5 / 5 (2) |
0
Peer-referral programs can increase HIV-testing in emergency departments
Researchers at the University of Cincinnati (UC) have found that incorporating a peer-referral program for HIV testing into emergency departments can reach new groups of high-risk patients and brings more patients into the ...
HIV & AIDS
May 17, 2013 |
not rated yet |
0
HIV no barrier to getting liver transplant, study finds
(HealthDay)—Liver transplants to treat a common type of liver cancer are a viable option for people infected with HIV, according to new research.
HIV & AIDS
May 17, 2013 |
not rated yet |
0
Study shows where scene context happens in our brain
In a remote fishing community in Venezuela, a lone fisherman sits on a cliff overlooking the southern Caribbean Sea. This man –– the lookout –– is responsible for directing his comrades on the water, ...
Monoclonal antibody appears effective and safe in asthma Phase IIa trial
A novel approach to obstructing the runaway inflammatory response implicated in some types of asthma has shown promise in a Phase IIa clinical trial, according to U. S. researchers.
New rice contamination reported in China
Authorities are investigating rice mills in southern China following tests that found almost half of the staple grain in one of the country's largest cities was contaminated with a toxic metal.
New tumour-killer shows great promise in suppressing cancers
Scientists from Nanyang Technological University (NTU) and Lund University, Sweden, have bioengineered a novel molecule which has been proven to successfully kill tumour cells.
Exercise levels may predict hospitalizations in COPD population
Clinical measurement of physical activity appears to be an independent predictor of whether or not patients with chronic obstructive pulmonary disease (COPD) will end up being hospitalized, according to a new study conducted ...
Delayed transfer to the ICU increases risk of death in hospital patients
Delayed transfer to the intensive care unit (ICU) in hospitalized patients significantly increases the risk of dying in the hospital, according to a new study from researchers in Chicago.